Friday, August 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Barclays Analyst Reiterates Underweight Rating on ZimVie with Revised Price Target

Elaine Mendonca by Elaine Mendonca
March 5, 2024
in Breaking News
0
Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands
0
SHARES
18
VIEWS
Share on FacebookShare on Twitter

Barclays analyst Matt Miksic has reiterated his Underweight rating on ZimVie (NASDAQ: ZIMV) with a revised price target. The new target is set at $16, up from the previous $13. This adjustment reflects Miksic’s cautious perspective on the stock’s potential compared to its industry peers and market benchmarks.

Overall, ZimVie’s performance is expected to be subdued in the near term, according to Miksic’s analysis.

ZIMV Stock Shows Positive Momentum Near 52-Week Highs on March 5, 2024

On March 5, 2024, ZIMV stock showed positive momentum as it traded near the top of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been performing well in the long term and is currently in an upward trend.

The price of ZIMV shares increased by $0.22 since the market last closed, representing a 1.30% rise. The stock closed at $17.15, showing a strong performance for the day. Despite this increase, the stock remained unchanged in after-hours trading, suggesting that investors are still evaluating the stock’s potential.

Overall, ZIMV’s performance on March 5, 2024, was positive, with the stock showing price momentum and trading near its highest levels in the past year. Investors may be optimistic about the company’s future prospects, leading to increased interest and trading activity in the stock.

ZIMV Stock Reports Mixed Performances for 2024: Revenue and Net Income Decline

On March 5, 2024, ZIMV stock experienced mixed performances as the company reported its financial results for the past year and the fourth quarter. According to data from CNN Money, ZIMV’s total revenue for the past year was $457.43 million, which decreased by 49.95% compared to the previous year. The total revenue for the fourth quarter was $113.07 million, which remained flat compared to the previous quarter.

In terms of net income, ZIMV reported a net loss of $393.28 million for the past year, which represents a significant decrease of 515.65% compared to the previous year. However, the net loss for the fourth quarter improved slightly to -$22.16 million, showing a 0.0% increase compared to the previous quarter.

Earnings per share (EPS) for ZIMV also showed a decline over the past year and the fourth quarter. The EPS for the past year was reported at -$14.87, which decreased by 507.02% compared to the previous year. The EPS for the fourth quarter was -$12.37, showing a significant decrease of 6347.91% compared to the previous quarter.

Overall, the financial performance of ZIMV on March 5, 2024, reflected a challenging year for the company with significant declines in total revenue, net income, and earnings per share. Investors and analysts will be closely monitoring the company’s future strategies and initiatives to improve its financial performance and drive growth in the coming quarters.

Tags: ZIMV
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Investment (5)

UBS Analyst Remains Bullish on Redwood Trust with Adjusted Price Target

5G Network

From 4G to 5G: How Airports Are Embracing Next-Generation Mobile Infrastructure

Finance_Budgeting (1)

Analyst Projections and Ratings for bluebird bio NASDAQ BLUE

Recommended

Palantir Stock

Palantir Shares Face Valuation Pressures Despite Strong Earnings

9 months ago
BridgeBio Pharma Stock

BridgeBio Pharma Investors Await Critical Heart Drug Data

9 months ago
Ocugen Stock

Ocugen’s Fresh $130M Cushion Sets the Stage for a Data-Heavy July and a Pivotal Regulatory Filing

1 month ago
Airbnb Stock

Navigating Regulatory Headwinds and Innovation: Airbnb’s Strategic Crossroads

10 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Kioxia’s Unsettling Arithmetic: Record Profits, a $229 Million Verdict, and a Stock Still Searching for Its Floor

French Top Court Settles Disputes Over Expert Fees, Strike Notices and the AGS Wage Guarantee

MSCI World ETF: Index Provider Rewrites the Rulebook for Fast-Moving Stocks

Airbus’ Paradox: A Slightly Smaller Forecast That Nobody Seems to Mind

Almonty Industries Rebounds From Index-Driven Exit as Tungsten Calculus Shifts Westward

OHB’s Two-Faced Half-Year: Record Orders Mask a Profit Squeeze That Spooked the Market

Trending

Nel ASA Stock
Analysis

Nel ASA’s Two-Speed Story: Orders Accelerate While the P&L Keeps Bleeding

by Jackson Burston
August 7, 2026
0

The Norwegian electrolyser maker Nel ASA is living a split-screen reality. Its order intake just exploded by...

SANDISK Stock

SanDisk’s $94 Billion Backlog Can’t Bridge the Gap Between Record Results and a Disappointed Market

August 7, 2026
Bitcoin Stock

Payrolls Shrink, Rate-Cut Bets Return, and Crypto’s Plumbing Wins

August 7, 2026
Kioxia Stock

Kioxia’s Unsettling Arithmetic: Record Profits, a $229 Million Verdict, and a Stock Still Searching for Its Floor

August 7, 2026
FALLBACK Stock

French Top Court Settles Disputes Over Expert Fees, Strike Notices and the AGS Wage Guarantee

August 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Nel ASA’s Two-Speed Story: Orders Accelerate While the P&L Keeps Bleeding
  • SanDisk’s $94 Billion Backlog Can’t Bridge the Gap Between Record Results and a Disappointed Market
  • Payrolls Shrink, Rate-Cut Bets Return, and Crypto’s Plumbing Wins

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com